FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971606170> ?p ?o ?g. }

• W1971606170 endingPage "28381" @default.
• W1971606170 startingPage "28370" @default.
• W1971606170 abstract "Blocking HIV-1 cell entry has long been a major goal of anti-HIV drug development. Here, we report a successful design of two highly potent chimeric HIV entry inhibitors composed of one CCR5-targeting RANTES (regulated on activation normal T cell expressed and secreted) variant (5P12-RANTES or 5P14-RANTES (Gaertner, H., Cerini, F., Escola, J. M., Kuenzi, G., Melotti, A., Offord, R., Rossitto-Borlat, I., Nedellec, R., Salkowitz, J., Gorochov, G., Mosier, D., and Hartley, O. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 17706–17711)) linked to a gp41 fusion inhibitor, C37. Chimeric inhibitors 5P12-linker-C37 and 5P14-linker-C37 showed extremely high antiviral potency in single cycle and replication-competent viral assays against R5-tropic viruses, with IC50 values as low as 0.004 nm. This inhibition was somewhat strain-dependent and was up to 100-fold better than the RANTES variant alone or in combination with unlinked C37. The chimeric inhibitors also fully retained the antiviral activity of C37 against X4-tropic viruses, and this inhibition can be further enhanced significantly if the target cell co-expresses CCR5 receptor. On human peripheral blood mononuclear cells, the inhibitors showed very strong inhibition against R5-tropic Ba-L strain and X4-tropic IIIB strain, with IC50 values as low as 0.015 and 0.44 nm, which are 45- and 16-fold better than the parent inhibitors, respectively. A clear delivery mechanism requiring a covalent linkage between the two segments of the chimera was observed and characterized. Furthermore, the two chimeric inhibitors are fully recombinant and are easily produced at low cost. These attributes make them excellent candidates for anti-HIV microbicides. The results of this study also suggest a potent approach for optimizing existing HIV entry inhibitors or designing new inhibitors. Blocking HIV-1 cell entry has long been a major goal of anti-HIV drug development. Here, we report a successful design of two highly potent chimeric HIV entry inhibitors composed of one CCR5-targeting RANTES (regulated on activation normal T cell expressed and secreted) variant (5P12-RANTES or 5P14-RANTES (Gaertner, H., Cerini, F., Escola, J. M., Kuenzi, G., Melotti, A., Offord, R., Rossitto-Borlat, I., Nedellec, R., Salkowitz, J., Gorochov, G., Mosier, D., and Hartley, O. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 17706–17711)) linked to a gp41 fusion inhibitor, C37. Chimeric inhibitors 5P12-linker-C37 and 5P14-linker-C37 showed extremely high antiviral potency in single cycle and replication-competent viral assays against R5-tropic viruses, with IC50 values as low as 0.004 nm. This inhibition was somewhat strain-dependent and was up to 100-fold better than the RANTES variant alone or in combination with unlinked C37. The chimeric inhibitors also fully retained the antiviral activity of C37 against X4-tropic viruses, and this inhibition can be further enhanced significantly if the target cell co-expresses CCR5 receptor. On human peripheral blood mononuclear cells, the inhibitors showed very strong inhibition against R5-tropic Ba-L strain and X4-tropic IIIB strain, with IC50 values as low as 0.015 and 0.44 nm, which are 45- and 16-fold better than the parent inhibitors, respectively. A clear delivery mechanism requiring a covalent linkage between the two segments of the chimera was observed and characterized. Furthermore, the two chimeric inhibitors are fully recombinant and are easily produced at low cost. These attributes make them excellent candidates for anti-HIV microbicides. The results of this study also suggest a potent approach for optimizing existing HIV entry inhibitors or designing new inhibitors." @default.
• W1971606170 created "2016-06-24" @default.
• W1971606170 creator A5000056939 @default.
• W1971606170 creator A5004932382 @default.
• W1971606170 creator A5064933402 @default.
• W1971606170 creator A5066988465 @default.
• W1971606170 creator A5070666446 @default.
• W1971606170 date "2011-08-01" @default.
• W1971606170 modified "2023-10-16" @default.
• W1971606170 title "Highly Potent Chimeric Inhibitors Targeting Two Steps of HIV Cell Entry" @default.
• W1971606170 cites W1558864286 @default.
• W1971606170 cites W1602599521 @default.
• W1971606170 cites W1654570214 @default.
• W1971606170 cites W1965987174 @default.
• W1971606170 cites W1966273882 @default.
• W1971606170 cites W1975258429 @default.
• W1971606170 cites W1977487387 @default.
• W1971606170 cites W1981587873 @default.
• W1971606170 cites W1982944348 @default.
• W1971606170 cites W1984811742 @default.
• W1971606170 cites W1987393778 @default.
• W1971606170 cites W1990028169 @default.
• W1971606170 cites W1991670386 @default.
• W1971606170 cites W1992758988 @default.
• W1971606170 cites W1994609426 @default.
• W1971606170 cites W1998885242 @default.
• W1971606170 cites W2002567921 @default.
• W1971606170 cites W2006770200 @default.
• W1971606170 cites W2009011206 @default.
• W1971606170 cites W2016967864 @default.
• W1971606170 cites W2030017358 @default.
• W1971606170 cites W2030648131 @default.
• W1971606170 cites W2031354156 @default.
• W1971606170 cites W2052392655 @default.
• W1971606170 cites W2053922567 @default.
• W1971606170 cites W2056949060 @default.
• W1971606170 cites W2060620553 @default.
• W1971606170 cites W2066121768 @default.
• W1971606170 cites W2069602336 @default.
• W1971606170 cites W2071866235 @default.
• W1971606170 cites W2072901265 @default.
• W1971606170 cites W2075009216 @default.
• W1971606170 cites W2082678461 @default.
• W1971606170 cites W2096211018 @default.
• W1971606170 cites W2097953079 @default.
• W1971606170 cites W2107316250 @default.
• W1971606170 cites W2107773522 @default.
• W1971606170 cites W2111105264 @default.
• W1971606170 cites W2112373415 @default.
• W1971606170 cites W2115059789 @default.
• W1971606170 cites W2117616142 @default.
• W1971606170 cites W2118730972 @default.
• W1971606170 cites W2126255146 @default.
• W1971606170 cites W2128135205 @default.
• W1971606170 cites W2140294338 @default.
• W1971606170 cites W2141685780 @default.
• W1971606170 cites W2143019707 @default.
• W1971606170 cites W2143312620 @default.
• W1971606170 cites W2145718464 @default.
• W1971606170 cites W2146478787 @default.
• W1971606170 cites W2146704167 @default.
• W1971606170 cites W2153747683 @default.
• W1971606170 cites W2154097024 @default.
• W1971606170 cites W2168045054 @default.
• W1971606170 cites W2169821755 @default.
• W1971606170 cites W2171687293 @default.
• W1971606170 cites W2172368341 @default.
• W1971606170 cites W2320400608 @default.
• W1971606170 doi "https://doi.org/10.1074/jbc.m111.234799" @default.
• W1971606170 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3151080" @default.
• W1971606170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21659523" @default.
• W1971606170 hasPublicationYear "2011" @default.
• W1971606170 type Work @default.
• W1971606170 sameAs 1971606170 @default.
• W1971606170 citedByCount "27" @default.
• W1971606170 countsByYear W19716061702012 @default.
• W1971606170 countsByYear W19716061702013 @default.
• W1971606170 countsByYear W19716061702014 @default.
• W1971606170 countsByYear W19716061702015 @default.
• W1971606170 countsByYear W19716061702017 @default.
• W1971606170 countsByYear W19716061702018 @default.
• W1971606170 countsByYear W19716061702019 @default.
• W1971606170 countsByYear W19716061702021 @default.
• W1971606170 countsByYear W19716061702022 @default.
• W1971606170 countsByYear W19716061702023 @default.
• W1971606170 crossrefType "journal-article" @default.
• W1971606170 hasAuthorship W1971606170A5000056939 @default.
• W1971606170 hasAuthorship W1971606170A5004932382 @default.
• W1971606170 hasAuthorship W1971606170A5064933402 @default.
• W1971606170 hasAuthorship W1971606170A5066988465 @default.
• W1971606170 hasAuthorship W1971606170A5070666446 @default.
• W1971606170 hasBestOaLocation W19716061701 @default.
• W1971606170 hasConcept C111919701 @default.
• W1971606170 hasConcept C137061746 @default.
• W1971606170 hasConcept C140704245 @default.
• W1971606170 hasConcept C147483822 @default.
• W1971606170 hasConcept C153911025 @default.
• W1971606170 hasConcept C159047783 @default.

• next